Publications

cemka > Publications

Classer les publications sur l'année

  • Pharmaco-EpidĂ©miologie

    Medical outcomes of glaucoma therapy from a Nationwide representative survey

    DENIS P, LAFUMA A, BERDEAUX G

    Clin Drug Investig ; 24(6):343-352

  • Pharmaco-EpidĂ©miologie

    EPIGRAM, Ă©tude phamacoĂ©pidĂ©miologique de l’obĂ©sitĂ© : mĂ©thodologie et critĂšres de qualitĂ©

    VRAY M, JOUBERT JM, ESCHWÈGE E, LIARD F, FAGNANI F, COMMENGES B, STEINBERG G, BÉGAUD B

    Thérapie ; 59(6):573-579

  • Pharmaco-EpidĂ©miologie

    Costs of rheumatoid arthritis in France : a multicenter study of 1109 patients managed by hospital-based rheumatologists

    GUILLEMIN F, DURIEUX S, DAURES JP, LAFUMA A, SARAUX A, SIBILIA J, BOURGEOIS P, SANY J

    J Rheumatol ; 31(7):1297-1304

  • Pharmaco-EpidĂ©miologie

    Comparison of Nd : YAG capsulotomy rates following phacoemulsification with implantation of PMMA, silicone, or acrylic intra-ocular lenses in four European countries

    AUFFARTH G, BRÉZIN A, CAPOROSSI A, LAFUMA A, MENDICUTE J, BERDEAUX G, SMITH A

    Ophthalmic Epidemiol ; 11(4):319-329

  • Pharmaco-EpidĂ©miologie

    Characteristics of patients with rheumatoid arthritis in France : a study of 1109 patients managed by hospital based rhumatologists

    SANY J, BOURGEOIS P, SARAUX A, DURIEUX S, LAFUMA A, DAURES JP, GUILLEMIN F, SIBILIA J

    Ann Rheum Dis ; 63(10):1235-1240

  • Pharmaco-EpidĂ©miologie

    Blindness, low vision, and other handicaps as risk factors attached to institutional residence

    BREZIN A,LAFUMA A, FAGNANI F, MESBAH M, BERDEAUX G

    Br J Ophtalmol ; 88(10):1330-1337

  • Pharmaco-EpidĂ©miologie

    An epidemiological model of genital herpes : application to France

    BOELLE PY, DETOURNAY B, VALLERON PJ, FAGNANI F, HALIOUA B, NICOLAS JC

    Ann Dermatol Venereol ; 131(1 Pt 1):17-26

  • Pharmaco-EpidĂ©miologie

    A population-based study of diabetes and its characteristics during the fasting month of ramadan in 13 countries

    SALTI I, BÉNARD E, DETOURNAY B, BIANCHI-BISCAY M, LE BRIGAND C, VOINET C, JABBAR A

    Diabetes Care ; 27(10):2306-2311

  • Pharmaco-EpidĂ©miologie

    A multicenter pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999

    LORTHOLARY O, CHARLEMAGNE A, BASTIDES F, CHEVALIER P, DATRY A, GONZALVES MF, MICHEL G, TILLEUL P, VEBER B, HERBRECHT R

    J Antimicrob Chemother ; 54(2):456-64

  • Économie de la santĂ©

    Effectiveness and cost of contraception in France (FACET study): a cohort study from the French National Healthcare Insurance Database.

    AGOSTINI A, GODARD C, LAURENDEAU C, BENMAHMOUD A, LAFUMA A, DOZ M, LEVY-BACHELOT L, GOURMELEN J, LINET T.

    European Journal of Obstetrics & Gynecology and Reproductive Biology ; 2018;229: 137–143

  • Autres

    Care pathway, towards the establishment of tailored funding: Reasons and criteria for success.

    EMERY G, LE FUR C, EPIS-DE-FLEURIAN AA, JOSSERAN A; Participants of Giens Round Table ‘Medico-economy’ of Giens XXXIII.

    Therapie ; 2018;73(1):33-40

  • Pharmaco-EpidĂ©miologie

    Health related quality of life in patients with community-acquired pneumococcal pneumonia in France.

    ANDRADE LF, SABA G, RICARD JD, MESSIKA J, GAILLAT J, BONNIN P, CHIDIAC C, ILLES HG, LAURICHESSE H, DETOURNAY B, PETITPRETZ P, DE POUVOURVILLE G.

    Health Qual Life Outcomes ; 2018;16 (1):28

  • Économie de la santĂ©

    Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis.

    CHARBONNEL B, SIMON D, DALLONGEVILLE J, BUREAU I, DEJAGER S, LEVY-BACHELOT L, GOURMELEN J, DETOURNAY B.

    Pharmacoecon Open ; 2018;2(2):209-219

  • Économie de la santĂ©

    Le traitement du diabùte de type 2 en France est dynamique plutît qu’inerte : analyse des prescriptions de 847 122 patients.

    ROUSSEL R, FONTAINE P, GOUET D, SERUSCLAT P, MARTINEZ L, DETOURNAY B, MARTIN-KRISTENSEN M.

    Med Mal Metab ; 2018;12(4):346-352

  • Pharmaco-EpidĂ©miologie

    L’Ă©valuation risque/bĂ©nĂ©fice dans les domaines de la santĂ© et de l’environnement : similitudes et diffĂ©rences

    FAGNANI F

    Environnement Risques & Santé ; 1(3):1-3